InnovAge stock posts 15.9 percent revenue growth for fiscal 2026

Published on 10/05/2026 at 17:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

InnovAge stock was trading at USD 8.95 on October 5, 2026, after fiscal 2026 revenue reached USD 989.7 million. Fiscal 2027 guidance targets adjusted EBITDA of USD 105 million to USD 115 million.

INNV, US45784A1043, Illustration mit AI erstellt.

InnovAge Holding Corp. (ISIN US45784A1043) was trading at USD 8.95 on Nasdaq at 11:37 a.m. ET on October 5, 2026, down 0.14 percent from the prior close. The central company story is stronger: fiscal 2026 revenue reached USD 989.7 million, an increase of 15.9 percent from USD 853.7 million in fiscal 2025, according to GlobeNewswire on September 8, 2026.

Revenue growth reaches 15.9 percent

The fiscal year ended June 30, 2026, brought a near break-even result. InnovAge reported a GAAP net loss of USD 0.7 million, compared with a USD 35.3 million loss in fiscal 2025, while adjusted EBITDA rose to USD 94.6 million from USD 34.5 million.

The fourth quarter supplied the clearest operating improvement. Revenue reached USD 261.951 million versus USD 221.417 million in the year-earlier quarter, and GAAP net income was USD 9.783 million compared with a USD 5.009 million loss. The company also reported 8,230 participants across 20 centers as of June 30, 2026, according to GlobeNewswire.

Fiscal 2027 guidance sets the test

Management issued fiscal 2027 guidance for revenue of USD 1.05 billion to USD 1.085 billion and adjusted EBITDA of USD 105 million to USD 115 million. The outlook also calls for an ending census of 8,625 to 8,850 participants and total member months of 101,000 to 102,500.

That guidance places profitability conversion ahead of simple expansion. InnovAge's fiscal 2026 adjusted EBITDA margin was 9.6 percent, compared with 4.0 percent in fiscal 2025, but the annual GAAP result remained negative after litigation-related charges. The distinction between adjusted profitability and shareholder earnings is therefore central to the stock's valuation.

Analysts see a wider target gap

KeyCorp raised its price target for InnovAge from USD 13.00 to USD 14.00 and maintained an Overweight rating in a report dated September 9, 2026, as MarketBeat reported.

The same MarketBeat report lists a Reduce consensus from four analysts and an average price target of USD 10.50. That target lies 17.32 percent above the USD 8.95 price on October 5, 2026, while the reported 52-week range was USD 3.94 to USD 12.64.

InnovAge stock stays below its yearly high

InnovAge stock was trading at USD 8.95 on Nasdaq on October 5, 2026, with a market capitalization of USD 1.2 billion and volume of 91,913 shares. The price stood USD 3.69 below the 52-week high, leaving the fiscal 2027 revenue and adjusted EBITDA targets as the next concrete benchmarks for the market.